Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-DOTA-Trastuzumab PET in Advanced HER2 Positive Breast Cancer Treated With Ado-trastuzumab Emtansine
NCT02226276Active, not recruiting
- Sponsor
- City of Hope
- Start
- Feb 2015
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of 64Cu-DOTA-trastuzumab in breast cancer, sponsored by City of Hope. Primary endpoints: Relationship Between Average Tumor Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response and Relationship Between Tumor Minimum Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response up to 1 year. Started Feb 2015; status: active, not recruiting.
02
Drugs
64Cu-DOTA-trastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02226276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02226276.